Dr. Loeb on the Results of Active Surveillance for Prostate Cancer

Video

Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Of the patients who could be considered candidates for active surveillance, one-fifth of those patients had higher Decipher scores, indicating a greater risk of aggressive disease, states Loeb. However, there were patients with intermediate-risk disease who had low Decipher scores.

Now that there are more testing options, patients do not have to rely on one biopsy test, explains Loeb. There are imaging and genomic tests that can give a patient more data and help determine if they are candidates for active surveillance.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD